2m 2m 2m 2m 2m 2m 2m
EDGEWISE THERAP (EWTX)
NASDAQ
$38.37+$1.87 (+5.12%)
Price as of Jun 23, 2026 7:47 PM EDT- $3.9BMarket Cap
- 157.40%1-Year Change
- BiotechnologyIndustry
EDGEWISE THERAP (EWTX)
$38.37+$1.87 (+5.12%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -151.4M +19.24% | -127.0M +39.67% | -90.9M +68.24% | -54.0M +67.86% | |
Depreciation and Amortization Expense | 2.1M +0.72% | 2.1M +33.40% | 1.6M +321.47% | 368,000 +35.29% | |
Total Operating Expenses | 191.4M +20.51% | 158.8M +38.89% | 114.4M +59.59% | 71.7M +65.82% | |
Operating Profit | -191.4M +20.51% | -158.8M +38.89% | -114.4M +59.59% | -71.7M +65.82% | |
Interest Income | 23.6M -5.63% | 25.0M +76.26% | 14.2M +253.26% | 4.0M +899.50% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 23.6M -5.63% | 25.0M +76.26% | 14.2M +253.26% | 4.0M +899.50% | |
Total Nonoperating Income and Expense | 23.6M -5.63% | 25.0M +76.26% | 14.2M +253.26% | 4.0M +899.50% | |
Income before Taxes | -191.4M +20.51% | -158.8M +38.89% | -114.4M +59.59% | -71.7M +65.82% | |
Income Taxes | 4,000 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -167.8M +25.40% | -133.8M +33.60% | -100.2M +48.08% | -67.6M +57.99% | |
Net Income from Continuing Operations Applicable to Common | -167.8M +25.40% | -133.8M +33.60% | -100.2M +48.08% | -67.6M +57.99% | |
Basic EPS and Net Income | -1.63 +12.41% | -1.45 -7.64% | -1.57 +24.60% | -1.26 +10.53% | |
Diluted EPS and Net Income | -1.63 +12.41% | -1.45 -7.64% | -1.57 +24.60% | -1.26 +10.53% | |
Basic Weighted Average Shares | 102.9M +11.38% | 92.4M +45.02% | 63.7M +18.90% | 53.6M +42.82% | |
Diluted Weighted Average Shares | 102.9M +11.38% | 92.4M +45.02% | 63.7M +18.90% | 53.6M +42.82% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 61.1M +46.76% | 41.7M -51.61% | 86.1M +291.47% | 22.0M +41.29% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 61.1M +46.76% | 41.7M -51.61% | 86.1M +291.47% | 22.0M +41.29% | |
Total Current Assets | 543.4M +14.28% | 475.5M +45.41% | 327.0M -8.40% | 357.0M +25.80% | |
Accumulated Depreciation | 6.8M +44.48% | 4.7M +79.09% | 2.6M +145.63% | 1.1M +51.71% | |
Property and Plant and Equipment and Net | 7.8M -17.59% | 9.5M -9.00% | 10.4M +22.38% | 8.5M +835.64% | |
Total Long-Term Assets | 262,000 0.00% | 262,000 -24.71% | 348,000 +38.65% | 251,000 -54.20% | |
Total Assets | 552.6M +13.51% | 486.8M +43.17% | 340.0M -7.37% | 367.1M +28.70% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 27.4M +14.71% | 23.9M +42.27% | 16.8M +1.12% | 16.6M +57.64% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 3.0M -20.45% | 3.7M -15.63% | 4.4M +1,247.72% | 329,000 0.00% | |
Total Liabilities | 30.3M +9.95% | 27.6M +30.16% | 21.2M +4.02% | 20.4M +87.88% | |
Retained Earnings | -546.4M +44.32% | -378.6M +54.67% | -244.8M +69.27% | -144.6M +87.89% | |
Total Stockholders Equity | 522.3M +13.73% | 459.2M +44.03% | 318.8M -8.04% | 346.7M +26.36% | |
Total Shares Outstanding | 106.2M +12.03% | 94.8M +34.61% | 70.5M +11.38% | 63.3M +27.79% | |
Cash Flow | |||||
Cash from Operating Activities | -143.8M +31.91% | -109.0M +18.58% | -91.9M +74.69% | -52.6M +57.09% | |
Capital Expenditures | 256,000 -80.49% | 1.3M -77.16% | 5.7M +3.59% | 5.5M +730.24% | |
Cash from Investing Activities | -32.8M -82.24% | -184.7M -279.48% | 102.9M +245.78% | -70.6M -70.86% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 196.1M -21.33% | 249.3M +368.82% | 53.2M -58.99% | 129.6M -30.45% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -32.29% -0.25% | -32.37% +14.25% | -28.33% +36.61% | -20.74% N/A | |
Return on Equity | -34.19% -0.60% | -34.40% +14.28% | -30.10% +38.19% | -21.78% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 19.85 -0.37% | 19.93 +2.21% | 19.50 -9.42% | 21.53 N/A | |
Cash Ratio | 2.23 +27.93% | 1.75 -65.98% | 5.13 +287.13% | 1.33 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow